Letter to the Editor: “The Effectiveness of Mediterranean Diet in Morbid Obese Patients After Laparoscopic Sleeve Gastrectomy”

Yıl 2021, Cilt: 5 Sayı: 3, 169 - 170, 22.12.2021

Ali Kırık , Hasan Gürel Sultan Türel , Hacer Şen

https://doi.org/10.46332/aemj.961389

Öz

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in our country and in the world. In the pathogenesis of NAFLD, lipid accumulation in the liver and peripheral insulin resistance play an important role. In the current literature, there are clinical studies examining the role of many medical agents, surgical methods, and diets in the treatment of NAFLD. However, the role of the Mediterranean diet in the treatment of NAFLD is not clear and prospective randomized controlled studies are needed.

Anahtar Kelimeler

Nonalcoholic fatty liver disease, sleeve gastrectomy, mediterranean diet

Editöre mektup: “Laparoskopik sleeve gastrektomi sonrası morbid obez hastalarda akdeniz diyetinin etkinliği”

Öz

Alkolik olmayan yağlı karaciğer hastalığı (AOYKH) ülkemizde ve dünyada en sık izlenen kronik karaciğer hastalığıdır. Hastalığın patogenezinde karaciğerde lipid birikimi ve periferik insülin direnci rol oynar. Güncel literatürde, birçok medikal ajan, cerrahi yöntem ve diyetin AOYKH tedavisindeki rolünü inceleyen klinik araştırma bulunmaktadır. Bununla beraber Akdeniz diyetinin AOYKH tedavisindeki rolü net değildir ve prospektif, randomize kontrollü çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Alkolik olmayan yağlı karaciğer hastalığı, sleeve gastrektomi, akdeniz diyeti

Kaynakça

• 1. Koşar M , Gündüz U , Dinçer O , Çakır T . Laparoskopik Sleeve Gastrektomi Sonrası Morbid Obez Hastalarda Akdeniz Diyetinin Etkinliği. Ahi Evran Med J. 2021; 5(1): 33-37.
• 2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
• 3. Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells. 2020;9(4):1005.
• 4. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007;189(6):W320-W323.
• 5. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486-1501.
• 6. Moore MP, Cunningham RP, Dashek RJ, Mucinski JM, Rector RS. A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD. Obesity. 2020;28(10):1843-1852.
• 7. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-846.
• 8. Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24(19):2083-2094.